TAK earnings
Takeda Pharmaceutical Company Limited (TAK) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis CareAbout 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda ((TAK) today announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that conven
- Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global MarketThe collaboration combines Innovent's proven immuno-oncology ("IO") and antibody-drug conjugate ("ADC") R&D capability and Takeda's experience in global oncology drug development to accelerate Innovent's two late-stage investigational medicines worldwide, and Takeda receives an option for an early-stage program.Innovent and Takeda will co-develop the IO backbone therapy IBI363 (PD-1/IL-2α-bias) globally and co-commercialize it in the U.S., where Takeda will lead the co-development and co-commercialization efforts under joint governance and aligned development plan; Takeda will receive exclusive commercialization rights outside Greater China and the U.S.Innovent will grant Takeda exclusive ri
- Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025– Takeda is the Leader in Orexin Science and is on Track to Submit Global Regulatory Applications Starting in Fiscal Year 2025 – Four Orexin Oral Presentations from Phase 3 Pivotal Studies Highlight Statistically Significant and Clinically Meaningful Improvement in Narcolepsy Type 1 Symptoms Demonstrating the Potential for a New Era of Care – Oveporexton was Generally Well-Tolerated with Safety Profile Consistent with Previous Clinical Studies Takeda ((TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861)1, a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist in narcolepsy type 1 (NT1), du
- Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia VeraRusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpoint All key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomes No serious adverse events considered related to rusfertide were reported Rusfertide has received Orphan Drug designation and Fast Track desig
- Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera− Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes − Rusfertide was generally well tolerated; no new safety findings were observed in the study Protagonist Therapeutics, Inc. ("Protagonist") ((PTGX) and Takeda ((TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all fou
- Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 GuidanceThird quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter
- Ligand Reports Second Quarter 2024 Financial ResultsConference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti
- AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's DiseaseAC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer's disease progressionAC Immune to receive upfront payment of $100 million upon closing and be eligible for an option exercise fee and additional potential milestones of up to approximately $2.1 billionAC Immune to host conference call and webcast today at 8:30 a.m. ET OSAKA, Japan, CAMBRIDGE, Massachusetts, and LAUSANNE, Switzerland, May 13, 2024 – Takeda (NYSE:TAK) and AC Immune SA (NASDAQ:ACIU)
- Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology AssetTakeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize Rusfertide, Protagonist's Investigational Injectable Hepcidin Mimetic Currently in Development for the Treatment of Polycythemia Vera (PV)Takeda Will Make an Upfront Payment of $300 Million at ClosingPartnership Combines Protagonist's Leadership in Pharmaceutical Peptide Drug Development With Takeda's Commercial Expertise and 70-Plus Year Legacy of Driving Innovation Within the Rare Hematology CommunityProtagonist to Host Conference Call and Webcast Today at 4:30 PM ETOSAKA, JAPAN, CAMBRIDGE, MA, and NEWARK, CA / ACCESSWIRE / Januar
- Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter ResultsConference Call and Webcast Today, August 7, 2023 at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal third quarter ended June 30, 2023. The company is hosting a conference call today, Aug. 7, 2023, at 4:30 p.m. ET to discuss the results. Webcast and Conference Call and Details Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register.vevent.com/register/BIcd0f2b791a4f4cdd97a1c
- Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results- Conference Call and Webcast Today, May 2, 2023 at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal second quarter ended March 31, 2023. The company is hosting a conference call today, May 2, 2023, at 4:30 p.m. ET to discuss the results. Webcast and Conference Call and Details Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register.vevent.com/register/BIf9cd65655e5444119df91
- HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China— HUTCHMED to receive US$400 million upfront on deal closing and up to US$730 million in potential future milestone payments, totaling up to US$1.13 billion, plus royalties on net sales — — Marketing authorization submissions in the U.S., Europe and Japan planned to complete in 2023 — — Partnership approach aligned with HUTCHMED's path to profitability and strategy to bring its innovative medicines to patients worldwide — — HUTCHMED to host a conference call and webcast at 8:30 a.m. EST (1:30 p.m. GMT / 9:30 p.m. HKT) on Monday, January 23, 2023 — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J. , Jan. 23, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: